Patient characteristics
| Characteristic | |
|---|---|
| Male sex, n (%) | 13 (21) |
| Age at diagnosis in years, median (range) | 58 (26–78) |
| Smoking status | |
| Former/current | 12 (20) |
| Never (<100 cigarettes lifetime) | 49 (80) |
| EGFR mutation, n (%) | |
| Exon 19 deletions | 41 (67) |
| Exon 18 E709A and G719A | 1 (2) |
| Exon 21 L858R | 19 (31) |
| Time on gefitinib or erlotinib (mo) | |
| Median (range) | 19 (7–78) |
| Age at enrollment in years, median (range) | 61 (27–80) |
| Karnofsky performance status at enrollment (%) | |
| 90% | 13 (21) |
| 80% | 37 (61) |
| 70% | 11 (18) |
| Lines of therapy before gefitinib/erlotinib (n%) | |
| 0 | 37 (61) |
| 1 | 20 (32) |
| 2 | 4 (7) |
| Lines of therapy after acquired resistance | |
| 0 | 41 (67) |
| 1 | 12 (20) |
| 2+ | 8 (13) |
| First-line gefitinib/erlotinib, n (%) | |
| Single agent | 29 (48) |
| With chemotherapy | 8 (13) |
| Maintenance after chemo | 5 (9) |
| Gefitinib/erlotinib/both, n (%) | |
| Erlotinib | 50 (82) |
| Gefitinib | 6 (10) |
| Gefitinib followed by erlotinib | 5 (8) |
| Acquired resistance to trial enrollment (mo) | |
| Median (range) | 6 (0–48) |